Received Oct 7, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MMR | MEASLES + MUMPS + RUBELLA (PRIORIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | — | IM |
IM administration; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of subcutaneous injection formulation administered by other route in a female patient who received MMR (Priorix) for prophylaxis. On 21-SEP-2025, the patient received the 1st dose of Priorix (intramuscular). On 21-SEP-2025, an unknown time after receiving Priorix, the patient experienced subcutaneous injection formulation administered by other route (Verbatim: IM administration). The outcome of the subcutaneous injection formulation administered by other route was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK receipt date :22-Sep-2025 The pharmacist asked that the route was SC (subcutaneous) in the box of Priorix, what if he/she did like IM (intramuscular), was that going to decrease the efficacy. The batch number was not provided upon follow up with the reporter. The Vaccine Administration Facility was the same as Primary Reporter.